Free Trial

153,746 Shares in Boston Scientific Corporation $BSX Purchased by Soros Capital Management LLC

Boston Scientific logo with Medical background

Key Points

  • Soros Capital Management LLC has made a new investment of $15.51 million in Boston Scientific Corporation, acquiring 153,746 shares, which now comprises approximately 4.0% of its total holdings.
  • Boston Scientific is currently rated as a "Buy" by most analysts, with three analysts giving it a "Strong Buy" rating and an average price target of $117.50.
  • In recent insider trading activities, CEO Michael F. Mahoney sold 164,443 shares of Boston Scientific, reflecting a 10.02% decrease in his position.
  • Looking to export and analyze Boston Scientific data? Unlock 5 Weeks of MarketBeat All Access for Just $5. Claim Your Limited-Time Discount.

Soros Capital Management LLC acquired a new stake in Boston Scientific Corporation (NYSE:BSX - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 153,746 shares of the medical equipment provider's stock, valued at approximately $15,510,000. Boston Scientific makes up 4.0% of Soros Capital Management LLC's portfolio, making the stock its 8th largest position.

Other hedge funds also recently made changes to their positions in the company. GAMMA Investing LLC increased its stake in Boston Scientific by 11,720.3% during the first quarter. GAMMA Investing LLC now owns 2,577,887 shares of the medical equipment provider's stock worth $260,057,000 after acquiring an additional 2,556,078 shares during the last quarter. Northern Trust Corp grew its stake in shares of Boston Scientific by 18.0% during the fourth quarter. Northern Trust Corp now owns 14,595,627 shares of the medical equipment provider's stock valued at $1,303,681,000 after buying an additional 2,221,790 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Boston Scientific by 18.7% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 10,839,362 shares of the medical equipment provider's stock valued at $968,172,000 after purchasing an additional 1,709,461 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Boston Scientific by 1.3% in the first quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider's stock valued at $13,577,311,000 after purchasing an additional 1,697,945 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its holdings in shares of Boston Scientific by 18.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 10,610,487 shares of the medical equipment provider's stock valued at $1,070,387,000 after purchasing an additional 1,664,108 shares during the period. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Boston Scientific Price Performance

BSX traded down $0.19 during trading on Friday, reaching $105.56. The company's stock had a trading volume of 4,066,690 shares, compared to its average volume of 7,483,518. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The firm has a fifty day simple moving average of $104.45 and a two-hundred day simple moving average of $102.17. Boston Scientific Corporation has a 1 year low of $79.53 and a 1 year high of $108.94. The company has a market cap of $156.41 billion, a price-to-earnings ratio of 62.83, a PEG ratio of 2.55 and a beta of 0.66.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.72 by $0.03. The firm had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business's revenue for the quarter was up 22.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insiders Place Their Bets

In other Boston Scientific news, Director Yoshiaki Fujimori sold 2,901 shares of the business's stock in a transaction on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total value of $310,377.99. Following the completion of the transaction, the director owned 2,081 shares in the company, valued at $222,646.19. The trade was a 58.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the business's stock in a transaction on Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the completion of the transaction, the executive vice president owned 23,600 shares of the company's stock, valued at approximately $2,469,268. This trade represents a 42.32% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 345,029 shares of company stock valued at $35,976,603. Corporate insiders own 0.50% of the company's stock.

Analyst Ratings Changes

A number of analysts have weighed in on the company. Wells Fargo & Company upped their target price on Boston Scientific from $118.00 to $124.00 and gave the stock an "overweight" rating in a report on Thursday, July 24th. Leerink Partnrs raised Boston Scientific to a "strong-buy" rating in a research report on Monday, June 16th. Robert W. Baird lifted their price objective on Boston Scientific from $117.00 to $123.00 and gave the company an "outperform" rating in a research note on Thursday, July 24th. UBS Group raised their target price on Boston Scientific from $130.00 to $135.00 and gave the company a "buy" rating in a research report on Thursday, July 24th. Finally, Needham & Company LLC restated a "buy" rating and set a $115.00 target price on shares of Boston Scientific in a research report on Wednesday, May 28th. Three analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have given a Hold rating to the company's stock. According to data from MarketBeat.com, Boston Scientific presently has an average rating of "Buy" and an average price target of $117.50.

Get Our Latest Stock Report on Boston Scientific

Boston Scientific Profile

(Free Report)

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Featured Stories

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Should You Invest $1,000 in Boston Scientific Right Now?

Before you consider Boston Scientific, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Boston Scientific wasn't on the list.

While Boston Scientific currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Tesla’s Future Unleashed: Elon’s Robotics Move Changes Everything
Top Trades: Massive Gains and Costly Mistakes to Avoid
NVIDIA Earnings: All Signs Point to More Growth Ahead

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines